Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) will release its second quarter 2021 financial results on August 3, 2021. The management team will host a conference call at 4:30 PM ET on the same day to discuss the results and provide corporate updates. Investors can access the call by dialing the provided numbers or via the webcast on the Company’s website. Deciphera focuses on developing innovative treatments for cancer, including its FDA-approved QINLOCK® for gastrointestinal stromal tumors.

Positive

• Management will discuss financial results and corporate updates in a live call.
• QINLOCK® is FDA-approved for fourth-line gastrointestinal stromal tumors.

Negative

• None.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, August 3, 2021, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 9943767. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors. For more information, visit https://www.deciphera.com/ or follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005370/en/

FAQ

When will Deciphera Pharmaceuticals report its second quarter 2021 financial results?

Deciphera Pharmaceuticals will report its second quarter 2021 financial results on August 3, 2021.

What time is the Deciphera Pharmaceuticals conference call?

The conference call will take place at 4:30 PM ET on August 3, 2021.

How can I access the Deciphera Pharmaceuticals conference call?

You can access the conference call by dialing (866) 930-5479 for domestic or (409) 216-0603 for international, using conference ID 9943767, or by visiting the Company’s website for a webcast.

What is QINLOCK® and its approval status?

QINLOCK® is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors.

Where can I find the archived webcast of the conference call?

The archived webcast will be available on Deciphera's website approximately two hours after the conference call and for 30 days following.